Abstract
More than 100 years ago, Pavlov discovered that the liver can remove enteric toxins. Now we think that, under normal circumstances, the liver can also remove bacteria, fungi, and their metabolites such as toxins, endotoxin, ammonia, indoles, phenols, short-chain fatty acids (C4–C6), pseudo-nerve delivery mass precursors. Gnotobiote research reveals that intestinal flora and endotoxin in the liver increase the number of Kupffer cells and play an important role in the improvement. When the functioning of the liver suffers damage (including chronic hepatitis, alcoholic and non-alcoholic fatty liver disease, cirrhosis, severe hepatitis, liver transplantation, etc.), the system will incur a gut microflora imbalance in varying degrees, damage to the intestinal barrier and allowing intestinal bacteria and its metabolites to enter extra-intestinal organs (including blood) , resulting in abdominal infection, endotoxemia and so on. Meanwhile, the inflammatory stimuli activate the immune system excessively, which can cause an abnormal immune response, leading to systemic inflammatory response syndrome (SIRS) or multiple organ failure, such as gastrointestinal dysfunction or failure. Endotoxemia, and gastrointestinal dysfunction can also increase the imbalance in gut microflora, and further aggravate liver injury, a vicious cycle. Through a series of basic and clinical microbial research of liver diseases, we found that probiotics can adjust the gut microflora, repairing and improving the intestinal barrier function and reducing intestinal bacterial translocation, decreasing endotoxemia, reducing infection and improving the functioning of the liver.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cesaro C, Tiso A, Del Prete A, et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis, 2011, 43:431–438.
Kan Z, Madoff D C. Liver anatomy: Microcirculation of the liver. Semin Intervent Radiol, 2008, 25:77–85.
Roberts M S, Magnusson B M, Burczynski F J, et al. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet, 2002, 41:751–790.
Abt M C, Artis D. The intestinal microbiota in health and disease: The influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol, 2009, 25:496–502.
Wheeler M D. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health, 2003, 27: 300–306.
Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol, 2010, 16: 1321–1329.
Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol, 2002, 8: 961–965.
Almeida J, Galhenage S, Yu J, et al. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol, 2006, 12: 1493–1502.
Bauer T M, Steinbruckner B, Brinkmann F E, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol, 2001, 96: 2962–2967.
Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: Effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol, 2001, 96: 1251–1255.
Morencos F C, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci, 1995, 40: 1252–1256.
Hashimoto N, Ohyanagi H. Effect of acute portal hypertension on gut mucosa. Hepatogastroenterology, 2002, 49: 1567–1570.
Wiest R, Rath H C. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol, 2003, 17: 397–425.
Norman K, Pirlich M. Gastrointestinal tract in liver disease: Which organ is sick? Curr Opin Clin Nutr Metab Care, 2008, 11: 613–619.
Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18: 353–372.
Heidelbaugh J J, Sherbondy M. Cirrhosis and chronic liver failure: Part II. Complications and treatment. Am Fam Physician, 2006, 74: 767–776.
Yoshida H, Hamada T, Inuzuka S, et al. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol, 1993, 88: 2067–2071.
Deschenes M, Villeneuve J P. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol, 1999, 94: 2193–2197.
Caly W R, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol, 1993, 18: 353–358.
Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology, 2001, 120: 726–748.
Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis, 2008, 28: 26–42.
Gines P, Angeli P, Lenz K, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010, 53: 397–417.
Nousbaum J B, Cadranel J F, Nahon P, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology, 2007, 45: 1275–1281.
Evans L T, Kim W R, Poterucha J J, et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology, 2003, 37: 897–901.
Gonzalez A R, Gonzalez G M, Albillos M A. Physiopathology of bacterial translocation and spontaneous bacterial peritonitis in cirrhosis. Gastroenterol Hepatol, 2007, 30: 78–84.
.Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: Is there a role for selective intestinal decontamination? Clin Sci (Lond), 2004, 107: 425–434.
Iwakiri Y, Groszmann R J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology, 2006, 43(2 Suppl 1): 5121–5131.
Bass N M, Mullen K D, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med, 2010, 362: 1071–1081.
Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology, 1990, 12(4 Pt 1): 716–724.
Rimola A, Bory F, Teres J, et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology, 1985, 5: 463–467.
Grange J D, Roulot D, Pelletier C, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: A double-blind randomized trial. J Hepatol, 1998, 29: 430–436.
Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med, 2003, 139: 186–193.
Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology, 1997, 25: 532–536.
Mattar A F, Drongowski R A, Coran A G, et al. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int, 2001, 17: 265–268.
Adawi D, Ahrne S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol, 2001, 70: 213–220.
Rayes N, Seehofer D, Muller AR, et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery — results of a prospective trial. Z Gastroenterol, 2002, 40: 869–876.
Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii Lal and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol, 2002, 37: 456–462.
Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology, 2003, 37: 1154–1164.
Liu Q, Duan Z P, Ha D K, et al. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 2004, 39: 1441–1449.
Asahara T, Takahashi M, Nomoto K, et al. Assessment of safety of lactobacillus strains based on resistance to host innate defense mechanisms. Clin Diagn Lab Immunol, 2003, 10: 169–173.
Gurusamy K S, Kumar Y, Davidson B R. Methods of preventing bacterial sepsis and wound complications for liver transplantation. Cochrane Database Syst Rev, 2008: CD006660.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Li, L. (2014). Infectious Microecology in Liver Disease. In: Li, L. (eds) Infectious Microecology. Advanced Topics in Science and Technology in China. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43883-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-43883-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43882-4
Online ISBN: 978-3-662-43883-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)